[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522302":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":23,"locations":36,"responsibleParty":49,"collaborators":51,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":23,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":23,"enrollmentInfo":71,"targetDuration":23,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":23,"overallStatus":80,"whyStopped":23,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Concurrent radiochemotherapy combined with immunotherapy","EXPERIMENTAL","Participants will receive toripalimab plus gemcitabine and nab-paclitaxel in cycles of 21 days. Non-progressors will plus concurrent radiotherapy during the 3rd cycle of chemotherapy. After 4-6 cycles treatment, Multiple disciplinary team (MDT) will evaluate whether to undergo radical surgery.",[13,14,15,16],"Drug: Toripalimab","Drug: Gemcitabine","Drug: Nab paclitaxel","Other: SBRT",[18,24,28,32],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Toripalimab","Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks",[9],null,{"type":19,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Gemcitabine","Gemcitabine 1000 mg\u002Fm\\^2 administered intravenously on Days 1 \\& 8 of every 3 weeks",[9],{"type":19,"name":29,"description":30,"armGroupLabels":31,"otherNames":23},"Nab paclitaxel","Nab paclitaxel 125 mg\u002Fm\\^2 administered intravenously on Days 1 \\& 8 of every 3 weeks.",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":23},"SBRT","SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\\*10 fractions, Planning target volume (PTV) 3Gy\\*10 fractions",[9],[37],{"facility":5,"status":23,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":23},"Nanjing","Jiangsu","210008","China","CN",{"type":44,"coordinates":45},"Point",[46,47],118.77778,32.06167,{"lat":47,"lon":46},{"type":50,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[52,54,56,58,60],{"name":53,"class":6},"The First Affiliated Hospital with Nanjing Medical University",{"name":55,"class":6},"Fudan University",{"name":57,"class":6},"Shanghai Changzheng Hospital",{"name":59,"class":6},"The First Affiliated Hospital of Soochow University",{"name":61,"class":6},"Xuzhou Central Hospital","100522302","phase-2-ag-combined-with-immunotherapy-and-sbrt-in-patients-with-potentially-resectable-pancreatic-cancer-100522302",false,"NCT06080854","AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer","Efficacy and Safety of AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer","Inclusion Criteria:\n\n1. Age \\>= 18 years；\n2. Eastern Cooperative Oncology Group (ECOG) score of 0-1;\n3. Pancreatic cancer confirmed by histology or cytology;\n4. Potentially resectable pancreatic cancer documented by contrast enhanced CT (or MRI) scan;\n5. Hematological indexes: Neutrophil count \\>= 1.5 x 10\\^9\u002FL Hemoglobin \\>= 10g \u002F dl Platelet count \\>= 100 x 10\\^9\u002FL; Biochemical indicators: Total bilirubin \\\u003C= 1.5 x upper limit of normal value (ULN); Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) \\\u003C 1.5 x ULN; Creatinine clearance rate \\>= 60ml \u002F min.\n6. Participants of childbearing age need to take appropriate protective measures (contraceptive measures or other methods of birth control) before entering the group and during the test;\n7. Signed informed consent;\n8. Follow the protocol and follow-up procedures.\n\nExclusion Criteria:\n\n1. Have received systematic anti-tumor treatment.\n2. Previous history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or bladder epithelial tumor (TA and TIS) or other malignant tumors that have received radical treatment (at least 5 years before enrollment).\n3. Active bacterial or fungal infection (\\> = level 2 of National Cancer Institute Common Toxicity Criteria (NCI-CTC), Version 3.0).\n4. Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases considered by researchers to be out of the group.\n5. Autoimmune diseases or immune defects who are treated with immunosuppressive drugs.\n6. Pregnant and lactating women. Pregnant women of childbearing age must be tested negative within 7 days before entering the group.\n7. Drug abuse, clinical or psychological or social factors make informed consent or research implementation affected.\n8. Allergic to programmed cell death protein-1 (PD-1) monoclonal antibody immunotherapy drugs.","ALL","18 Years",{"count":72,"type":73},108,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with potentially resectable pancreatic cancer.",[79],"Pancreatic Carcinoma","NOT_YET_RECRUITING","2023-10-06",{"date":83,"type":84},"2023-10-12","ACTUAL",{"date":86,"type":73},"2023-11-10",{"date":88,"type":73},"2026-06-06",{"name":5,"class":6},1]